Bolag
Magle Group bygger på strategiska förvärv som syftar till att driva tillväxt och diversifiera risker. Idag omfattar koncernen tre verksamhetsområden. Magle Chemoswed, en kontraktsutvecklings- och tillverkningsorganisation (CDMO). Magle PharmaCept, ett försäljnings- och marknadsföringsföretag för utveckling och direktförsäljning av koncernens medicintekniska produkter, och Magle Biopolymers A/S, en specialiserad tillverkningsorganisation för Dextran-teknologi.
Bolagets senaste flöde, utan extra fluff.
Magle Group’s Q4 report highlights restructuring measures, portfolio clean-up and a focus on improving profitability in a challenging financial environment.
On 25 March 2026 Magle Chemoswed Holding AB (publ) (“Magle Group”, the “Company” or the “Group) announced that it had, inter alia, reached an agreement with holders of its senior secured bonds 2025/2028 with ISIN SE0025197403 (the “Bonds”). The Company hereby announces that the Company, through Nordic Trustee & Agency AB (publ) as agent under the Bonds, today has initiated a written procedure (the "Written Procedure") regarding certain amendments and waivers to the terms and conditions of its Bonds.
Aktieägarna i Magle Chemoswed Holding AB (publ), org.nr 556913-4710 ("Bolaget"), kallas härmed till extra bolagsstämma den 10 april 2026, kl. 09:00 i Bolagets lokaler på Agneslundsvägen 20B i Malmö. Registrering till den extra bolagsstämman börjar kl. 08:30.
The Board of Directors of Magle Group AB (publ) (“Magle Group”, the “Company” or the “Group”) has today resolved, subject to approval by an extraordinary general meeting (the “Extraordinary General Meeting”), on a rights issue of shares of approximately SEK 40 million (the “Rights Issue”) to strengthen the Company's balance sheet and financial flexibility, support working capital and operational efficiency in the core businesses, and enable scalable growth. The subscription price is SEK 4.50 per share. The Rights Issue is covered up to approximately 85 percent through subscription undertakings, subscription intentions and a guarantee commitment. In addition, the Company has secured bridge financing pending the completion of the Rights Issue, reached an agreement in principle with holders representing a majority of its outstanding bonds including a conditional waiver of the maintenance test until 31 December 2026, subject to the Company raising aggregate net cash of at least SEK 100 million, including the net proceeds from the Rights Issue, by 30 June 2026, and entered into amended loan agreements with PRS1 ApS (“PRS1”) and MB Holding Køge ApS (“MB Holding”). Notice to the Extraordinary General Meeting, to be held on 10 April 2026, for resolution on approval of the Rights Issue and the related party transactions relating to the amended loan agreements with PRS1 and MB Holding, will be announced through a separate press release.
Magle Chemoswed Holding AB (“Magle Chemoswed”) today announces that Magle Chemoswed Holding AB and its subsidiary Magle Biopharma AB (together, the “Licensors”) have entered into an exclusive license agreement (the “Agreement”) with Aktiebolaget Grundstenen 178422 which has applied for a name change to Alvion Bio AB (“Alvion Bio”), granting Alvion Bio exclusive worldwide rights to develop and commercialise the Group’s amniotic stem cell technology.
Magle Group today issues a profit warning in advance of the publication of its Q4 2025 Interim Report and Full-Year 2025 Results, now scheduled for release on March 27, 2026.
Magle Group today announces a strategic direction focused on strengthening profitability, operational discipline, and long-term value creation. The Group will prioritise its most established revenue-generating platforms - Magle Biopolymers and Magle Chemoswed, while reducing emphasis on early-stage biotech development and exploratory innovation.
Magle Group today announces that Fredrik Andersson, Chief Operating Officer, will step down from his position during the coming months, as part of a planned leadership transition. This decision has been made for personal reasons, as Fredrik looks to open a new chapter in life with more time for family and the opportunity to explore other professional avenues.
Stig Lökke Pedersen (Styrelseordförande) har förvärv 5 865 aktie för 88 913 SEK